Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable ≥Vgpr Responses Among Immunomodulatory / Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

Beksaç, Meral; Paydaş, Semra; Tuğlular, Tülin; Arslan, Önder; Göker, Hakan; Kaynar, Leylagül; Altuntaş, Fevzi; Atalay, Figen; Teke, Havva Üsküdar; Bolaman, Ali Zahit; Pehlıvan, Mustafa; Sönmez, Mehmet; Demir, Ahmet Muzaffer; Topçuoğlu, Pervin; Yılmaz, Mehmet; Kabukcu, Sibel; Albayrak, Murat; Yurttaş, Nurgül Özgür; Salihoğlu, Ayşe; Çakar, Merih Kızıl; Gürman, Günhan

doi:10.1016/j.clml.2019.09.402

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Forty-three patients with a median of 4 prior lines of therapy (range 2-10) including PIs and IMIDs or double refractory (66% post-AuSCT) were retrospectively evaluated after a salvage treatment with elotuzumab combined with dexamethasone and with either lenalidomide (Elo-Rd, n = 23) or pomalidomide (Elo-Pd, n = 20) [91]. The median number of cycles was 4 (range 1-81) for Elo-Rd and 3 in the Elo-Pd group.…”

Section: Elotuzumab In Combination With Imidsmentioning

confidence: 99%

Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses

Musto

Rocca

2020

Expert Review of Hematology

View full text Add to dashboard Cite

Introduction: In the last few years, monoclonal antibodies have rapidly modified the therapeutic strategies for treating patients with multiple myeloma. Areas covered: In this review, the most recent literature data regarding indications for which monoclonal antibodies are currently or will be shortly approved as salvage therapies in relapsed/refractory myeloma are discussed. In particular, updated results until March 22, 2020 of antibodies directed against CD38 (daratumumab and isatuximab), SLAMF7 (elotuzumab), BCMA (GSK2857916/belantamab mafodotin), and PD-1/PD-1 L axis (nivolumab and pembrolizumab) will be analyzed in detail. Expert opinion: Monoclonal antibodies represent a new, very effective approach that will open novel and dynamic treatment scenarios for myeloma patients in the coming years. Optimal positioning and selection of different antibodies that are or will be soon available, appropriate combinations and careful evaluation of possible new toxicities should be considered in the future management of these patients.

show abstract

Section: Elotuzumab In Combination With Imidsmentioning

confidence: 99%